References
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.
Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007; 109: 3489–3495.
Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78: 288–294.
Gertz M . Managing plasma cell leukemia. Leuk Lymphoma 2007; 48: 5–6.
Blade J, Kyle RA . Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999; 13: 1259–1272.
Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terré C, Lafage-Pochitaloff M et al. Cytogenetic, interphase and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia. A study of 40 cases at diagnosis. Blood 2001; 97: 822–825.
Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114: 665–667.
Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D’Arena G et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109: 2285–2290.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Avet-Loiseau, H., Roussel, M., Campion, L. et al. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia 26, 158–159 (2012). https://doi.org/10.1038/leu.2011.176
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.176
- Springer Nature Limited
This article is cited by
-
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
Leukemia (2020)
-
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
Leukemia (2018)
-
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Blood Cancer Journal (2018)
-
Risk Stratification in Multiple Myeloma
Current Hematologic Malignancy Reports (2016)
-
Primary Plasma Cell Leukemia: Identity Card 2016
Current Treatment Options in Oncology (2016)